Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Cancer: early-phase trial registry
108 of 188 indexed Endometrial Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #59 of 28,707 conditions by registered trial count.
188 US clinical trials · 108 currently recruiting · #59 of 28,707 conditions by registered trial count
Endometrial Cancer: 188 US clinical trials tracked, 108 recruiting.
Endometrial Cancer is the subject of 188 registered US clinical trials on ClinicalTrials.gov, 108 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition endometrial-cancer
OPEN 108 | RECR 57% | LATE 15 | EARLY 118 | RANK #59 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Mesothelioma (57% recruiting · 47 trials)
Endometrial Cancer lists 108 open slots (57% of 188 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Cancer is recruiting above its size-band peers.
108 of 188 indexed trials (57.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Endometrial Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 188 trials (9%). 116 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 182 trials that report a genuine target (sentinel values excluded). 85 of those (46.7%) plan for fewer than 100 participants.
-
Endometrial Cancer research is mostly interventional.
167 interventional and 21 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
188 total, page 3 of 4
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America
NCT06943521
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
Abramson Cancer Center at Penn Medicine
NCT05758688
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Panagiotis Konstantinopoulos, MD, PhD
NCT06518564
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
Jessica D. St. Laurent, MD
NCT07220239
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
NCT05819892
CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer
Abramson Cancer Center at Penn Medicine
NCT07278986
A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT07318415
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Radiopharm Theranostics
NCT05799274
Estrogen, Diet, Genetics and Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT00587886
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Exelixis
NCT03170960
Improving Care After Inherited Cancer Testing
Vanderbilt-Ingram Cancer Center
NCT04763915
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Merck Sharp & Dohme
NCT06132958
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Gilead Sciences
NCT06486441
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company
NCT04188548
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus
NCT03860272
Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation
Frederick R. Ueland, M.D.
NCT02658565
Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]
Karyopharm Therapeutics
NCT03555422
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
University of Washington
NCT04930159
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Incyte Corporation
NCT04463771
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
NCT05677048
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Xencor
NCT05032040
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
University of Oklahoma
NCT03526432
Diet, Hepcidin, and Chemotherapy RDI
George Washington University
NCT06483997
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure
NCT05572684
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
NCT01797523
Risk Factors for Endometrial Cancer in Black Women
Memorial Sloan Kettering Cancer Center
NCT00514254
Abemaciclib and Letrozole to Treat Endometrial Cancer
Gynecologic Oncology Group
NCT04393285
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
University of Oklahoma
NCT03932409
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT04569773
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT02285192
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
NCT01068249
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
Hoffmann-La Roche
NCT05634499
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
Medical College of Wisconsin
NCT03694262
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer
Rutgers, The State University of New Jersey
NCT05220033
Genetic Testing in African Americans
Augusta University
NCT05591131
A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03285152
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
NCT03835819
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
NCT06710847
Activity and Cancer Survivorship Exercise Pilot
University of Iowa
NCT07283029
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
NCT03955978
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
NCT05761951
Continuation of Follow-up of DES-Exposed Cohorts
National Cancer Institute (NCI)
NCT00340600
Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples
National Cancer Institute (NCI)
NCT01793545
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
AEterna Zentaris
NCT01767155
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma
NCT02632448
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 74 |
| Phase 2 | 44 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Cancer page
188 registered trials, 108 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 108 Endometrial Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Endometrial Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Cancer condition card totals 188 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.